• Phase II of the antibiotic candidate DNV3837 ongoing – end of the first part of the trial (DSMB) expected in Q4 2021
  • Strengthening of screening and analytical capacities with three complementary calls for projects won by DEINOVE
  • Group net income for the first half of 2020 of -€3.1M compared to -€4.6M in 2020, mainly thanks to lower operating expenses
○ Restructuring of operations with a 24% decrease in operating expenses (€4.1M vs. €5.5M in 2020), still 84% dedicated to R&D
  • Group cash position:
○  Balance of +€3.4M at June 30, 2021, compared to +€2.9M at June 30, 2020
○ On January 20, 2021, the 5th tranche of OCA was subscribed by the ESGO Fund, for an amount of €3M
○ Implementation of a new agreement with the ESGO Fund of notes convertible into new shares for a maximum nominal amount of €10M and issuance of a first €500,000 tranche on September 14, 2021


DEINOVE (Euronext Growth Paris: ALDEI), a French biotech company, pioneer in the exploration and exploitation of bacterial biodiversity to address the urgent, global challenge of antibiotic resistance, announces that its Board of Directors has approved the consolidated financial statements for the first half of 2021.

“This first half-year symbolizes the recognition of the quality of DEINOVE's science and approach. The Company has been selected in three highly competitive and complementary calls for projects and selected by independent scientific committees that validate the Company's approach. The deployment of cutting-edge technologies associated with these projects reinforces the leadership of DEINOVE's platform in the fight against antimicrobial resistance”, commented Alexis RIDEAU, CEO of DEINOVE. He added, “These non-dilutive financings have been complemented by a convertible bond financing that allows us to fund the company through the next value-creating step of our clinical program with our antibiotic candidate DNV3837.”